These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 34461489)

  • 1. Metabolomics of prostate cancer: Knock-in versus knock-out prostate.
    Kumar D; Bansal N; Gupta A; Mandhani A; Lal H; Kumar M; Sankhwar SN
    J Pharm Biomed Anal; 2021 Oct; 205():114333. PubMed ID: 34461489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
    Kumar D; Gupta A; Mandhani A; Sankhwar SN
    Prostate; 2016 Sep; 76(12):1106-19. PubMed ID: 27197810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status.
    Dudka I; Thysell E; Lundquist K; Antti H; Iglesias-Gato D; Flores-Morales A; Bergh A; Wikström P; Gröbner G
    BMC Cancer; 2020 May; 20(1):437. PubMed ID: 32423389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of emerging metabolomics-based biomarkers of prostate cancer: a systematic review.
    Bansal N; Kumar M; Sankhwar SN; Gupta A
    Expert Rev Mol Med; 2022 Jun; 24():e25. PubMed ID: 35730322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomics-derived prostate cancer biomarkers: fact or fiction?
    Kumar D; Gupta A; Mandhani A; Sankhwar SN
    J Proteome Res; 2015 Mar; 14(3):1455-64. PubMed ID: 25609016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
    Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
    Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy.
    Strand SH; Bavafaye-Haghighi E; Kristensen H; Rasmussen AK; Hoyer S; Borre M; Mouritzen P; Besenbacher S; Orntoft TF; Sorensen KD
    Int J Cancer; 2019 Dec; 145(12):3445-3452. PubMed ID: 31125115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
    Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive urine metabolomics of prostate cancer and its therapeutic approaches: a current scenario and future perspective.
    Kumar D; Nath K; Lal H; Gupta A
    Expert Rev Proteomics; 2021 Nov; 18(11):995-1008. PubMed ID: 34821179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of metabolites associated with prostate cancer risk: a nested case-control study with long follow-up in the Northern Sweden Health and Disease Study.
    Röhnisch HE; Kyrø C; Olsen A; Thysell E; Hallmans G; Moazzami AA
    BMC Med; 2020 Jul; 18(1):187. PubMed ID: 32698845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating microRNAs in plasma before and after radical prostatectomy.
    McDonald AC; Raman JD; Shen J; Liao J; Pandya B; Vira MA
    Urol Oncol; 2019 Nov; 37(11):814.e1-814.e7. PubMed ID: 31421994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.
    Ouellet V; Aprikian A; Bergeron A; Brimo F; Bristow RG; Chevalier S; Drachenberg D; Fazli L; Fleshner NE; Gleave M; Karakiewicz P; Klotz L; Lacombe L; Lattouf JB; van der Kwast T; Squire JA; Latour M; Trudel D; Mes-Masson AM; Saad F
    BMC Urol; 2018 Sep; 18(1):78. PubMed ID: 30200929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
    Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
    Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells.
    Laursen EB; Fredsøe J; Schmidt L; Strand SH; Kristensen H; Rasmussen AKI; Daugaard TF; Mouritzen P; Høyer S; Kristensen G; Stroomberg HV; Brasso K; Røder MA; Borre M; Sørensen KD
    Am J Pathol; 2019 Dec; 189(12):2377-2388. PubMed ID: 31539518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMR-based metabolomics studies of human prostate cancer tissue.
    Lima AR; Pinto J; Bastos ML; Carvalho M; Guedes de Pinho P
    Metabolomics; 2018 Jun; 14(7):88. PubMed ID: 30830350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel non-canonical Wnt signature for prostate cancer aggressiveness.
    Sandsmark E; Hansen AF; Selnæs KM; Bertilsson H; Bofin AM; Wright AJ; Viset T; Richardsen E; Drabløs F; Bathen TF; Tessem MB; Rye MB
    Oncotarget; 2017 Feb; 8(6):9572-9586. PubMed ID: 28030815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy.
    Li X; Zhang W; Song J; Zhang X; Ran L; He Y
    Clin Epigenetics; 2019 Jul; 11(1):99. PubMed ID: 31288850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.
    Grosset AA; Ouellet V; Caron C; Fragoso G; Barrès V; Delvoye N; Latour M; Aprikian A; Bergeron A; Chevalier S; Fazli L; Fleshner N; Gleave M; Karakiewicz P; Lacombe L; Lattouf JB; van der Kwast T; Trudel D; Mes-Masson AM; Saad F;
    PLoS Med; 2019 Jul; 16(7):e1002847. PubMed ID: 31265453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
    Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
    BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
    Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
    Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.